fig3
Figure 3. Overall and progression-free survival with ICI plus chemotherapy for the first-line treatment of advanced/recurrent EC. ICI: Immune checkpoint inhibitor; EC: endometrial cancer.
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Navigation
Committee on Publication Ethics
https://members.publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
